Ranbaxy loses exclusivity on heartburn drug in US || Investment Idea

Drug maker Ranbaxy’s troubles with the US Food and Drug Administration (FDA) continue, with the American regulator allowing Israel-based Teva Pharma to launch the generic of Nexium, a heartburn medicine from the AstraZeneca stable. Nexium makes about $4 billion in global sales. Ranbaxy’s loss, meanwhile, could be gain for drug major Cipla, which provides Teva Pharma formulations for Nexium generic. Teva’s benefit from an early entry into one of the biggest drug opportunities will have a rub-off on the Mumbai-based Cipla.

 

Investment Idea

- BUY NCC ABOVE 76 TARGETS-76.7,77.4,78.1 SL-74.5 .

- SELL JINDAL SAW BELOW 88.6 TARGETS- 87.8,87,86.2              SL-90.2 .